Despite the ability of glucocorticoids to prevent blindness and provide clinical remission of GCA, their inability to suppress the Th1 pathway requires further investigation into the long-term outcomes of high IFN-gamma levels in GCA patients and whether it allows the continued progression of the illness. This evidence concerns the gene IFNG and temporal arteritis.